Colorectal cancer screening: the time to act is now
BMC Medicine 2015, 13:262 (13 October 2015)
Hermann Brenner and colleagues argue that colorectal cancer deaths can be avoided by implementation of screening programs and increased media attention to improve awareness, and highlight future avenues of research which can reduce the burden of disease
Pre-diagnostic concordance with the WCRF/AICR guidelines and survival in European colorectal cancer patients: a cohort study
BMC Medicine 2015, 13:107 (7 May 2015)
Healthier lifestyle behavior is associated with better survival in colorectal cancer (CRC) patients, emphasizing the benefit of following the existing diet and exercise recommendations for cancer prevention.
Altered pathways and colorectal cancer prognosis
BMC Medicine 2015, 13:76 (8 April 2015)
Victor Moreno and Rebeca Sanz-Pamplona comment on research demonstrating a link between gene pathway de-regulation and colon cancer prognosis, emphasizing that following validation, the findings will shed light on the mechanisms of carcinogenesis.
Improved survival among colon cancer patients with increased differentially expressed pathways
BMC Medicine 2015, 13:75 (8 April 2015)
In an analysis of genes that are differentially expressed in colon cancer, having more de-regulated pathways is associated with improved survival, providing insights into the links between differential gene expression and colon cancer prognosis.
Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?
BMC Medicine 2015, 13:56 (19 March 2015)
Neville Yeomans comments on a recent consensus statement regarding use of nonsteroidal anti-inflammatory drugs (NSAIDs), and highlights potential side-effects on the whole gastrointestinal tract, and the cardiovascular risks that have yet to be determined.
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
BMC Medicine 2013, 11:59 (4 March 2013)
The KRAS mutation in codon 12 (G12D) is associated with poorer survival of metastatic colorectal cancer patients treated with intensive triplet chemotherapy plus bevacizumab compared with patients having wild type or different KRAS genotypes.